MedTrace Logo

AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

NCT04993391 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2022-10-26

No results posted yet for this study

Summary

This is a phase I/II, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, PK profile and efficacy of JS111 for patients with Non-small cell lung cance. This study is divided into 3 periods: dose escalation stage, dose extension stage, and efficacy extension stage.

Conditions

Interventions

DRUG

JS111(AP-L1898 Capsules)

40 mg, QD

DRUG

JS111(AP-L1898 Capsules)

80 mg, QD

DRUG

JS111(AP-L1898 Capsules)

160 mg, QD

DRUG

JS111(AP-L1898 Capsules)

240 mg, QD

DRUG

JS111(AP-L1898 Capsules)

320 mg, QD

Sponsors & Collaborators

  • Suzhou Junjing BioSciences Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-13
Primary Completion
2024-06-18
Completion
2024-08-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04993391 on ClinicalTrials.gov